671 related articles for article (PubMed ID: 33686483)
1. Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland.
Jeyam A; Gibb FW; McKnight JA; Kennon B; O'Reilly JE; Caparrotta TM; Höhn A; McGurnaghan SJ; Blackbourn LAK; Hatam S; McCrimmon RJ; Leese G; Lindsay RS; Petrie J; Chalmers J; Philip S; Wild SH; Sattar N; McKeigue PM; Colhoun HM;
Diabetologia; 2021 Jun; 64(6):1320-1331. PubMed ID: 33686483
[TBL] [Abstract][Full Text] [Related]
2. Flash monitor initiation is associated with improvements in HbA
Jeyam A; Gibb FW; McKnight JA; O'Reilly JE; Caparrotta TM; Höhn A; McGurnaghan SJ; Blackbourn LAK; Hatam S; Kennon B; McCrimmon RJ; Leese G; Philip S; Sattar N; McKeigue PM; Colhoun HM;
Diabetologia; 2022 Jan; 65(1):159-172. PubMed ID: 34618177
[TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin.
Reid LJ; Gibb FW; Colhoun H; Wild SH; Strachan MWJ; Madill K; Dhillon B; Forbes S
Diabetologia; 2021 Aug; 64(8):1725-1736. PubMed ID: 33966091
[TBL] [Abstract][Full Text] [Related]
5. HbA
Evans-Cheung TC; Campbell F; Yong J; Parslow RC; Feltbower RG
Diabet Med; 2019 Jan; 36(1):88-95. PubMed ID: 30059173
[TBL] [Abstract][Full Text] [Related]
6. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
[TBL] [Abstract][Full Text] [Related]
7. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion.
Lepore G; Bonfanti R; Bozzetto L; Di Blasi V; Girelli A; Grassi G; Iafusco D; Laviola L; Rabbone I; Schiaffini R; Bruttomesso D;
Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):335-342. PubMed ID: 29428572
[TBL] [Abstract][Full Text] [Related]
8. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
Rautiainen P; Tirkkonen H; Laatikainen T
Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
[TBL] [Abstract][Full Text] [Related]
9. Treatment Modality-Dependent Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes: Danish Adult Diabetes Database Study.
Hoshina S; Andersen GS; Jørgensen ME; Ridderstråle M; Vistisen D; Andersen HU
Diabetes Technol Ther; 2018 Mar; 20(3):229-234. PubMed ID: 29437465
[TBL] [Abstract][Full Text] [Related]
10. Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
Shalitin S; Gil M; Nimri R; de Vries L; Gavan MY; Phillip M
Diabet Med; 2010 Mar; 27(3):339-47. PubMed ID: 20536498
[TBL] [Abstract][Full Text] [Related]
11. Glycaemic control in transition-aged versus early adults with type 1 diabetes and the effect of a government-funded insulin pump programme.
Mooney SP; Booth GL; Shulman R; Na Y; Weisman A; Shah BR; Perkins BA; Lipscombe L
Diabet Med; 2021 Nov; 38(11):e14618. PubMed ID: 34076916
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of insulin pump therapy on glycemic control in adults with type 1 diabetes mellitus.
Orr CJ; Hopman W; Yen JL; Houlden RL
Diabetes Technol Ther; 2015 Jan; 17(1):49-54. PubMed ID: 25317602
[TBL] [Abstract][Full Text] [Related]
13. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
[TBL] [Abstract][Full Text] [Related]
14. Use of continuous subcutaneous insulin infusion versus multiple daily injections in emerging adults with type 1 diabetes is associated with better clinical engagement but not glycaemic control.
Chai TYL; Farrell K; Holmes-Walker DJ
Intern Med J; 2023 Feb; 53(2):255-261. PubMed ID: 34561942
[TBL] [Abstract][Full Text] [Related]
15. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M
Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639
[TBL] [Abstract][Full Text] [Related]
16. Continuous Subcutaneous Insulin Infusion in Adult Type 1 Diabetes Mellitus Patients: Results from a Public Health System.
Moreno-Fernandez J; Gomez FJ; Pinés P; González J; López J; López LM; Blanco B; Roa C; Herranz S; Muñoz-Rodríguez JR
Diabetes Technol Ther; 2019 Aug; 21(8):440-447. PubMed ID: 31199682
[No Abstract] [Full Text] [Related]
17. Diabetic Ketoacidosis at Onset of Type 1 Diabetes and Long-term HbA1c in 7,961 Children and Young Adults in the Australasian Diabetes Data Network.
Clapin HF; Earnest A; Colman PG; Davis EA; Jefferies C; Anderson K; Chee M; Bergman P; de Bock M; Kao KT; Fegan PG; Holmes-Walker DJ; Johnson S; King BR; Mok MT; Narayan K; Peña Vargas AS; Sinnott R; Wheeler BJ; Zimmermann A; Craig ME; Couper JJ;
Diabetes Care; 2022 Dec; 45(12):2918-2925. PubMed ID: 36749868
[TBL] [Abstract][Full Text] [Related]
18. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.
Beck RW; Riddlesworth TD; Ruedy KJ; Kollman C; Ahmann AJ; Bergenstal RM; Bhargava A; Bode BW; Haller S; Kruger DF; McGill JB; Polonsky W; Price D; Toschi E;
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):700-708. PubMed ID: 28711468
[TBL] [Abstract][Full Text] [Related]
19. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years.
Jakisch BI; Wagner VM; Heidtmann B; Lepler R; Holterhus PM; Kapellen TM; Vogel C; Rosenbauer J; Holl RW;
Diabet Med; 2008 Jan; 25(1):80-5. PubMed ID: 18199134
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Effects of Continuous Subcutaneous Insulin Infusion on Glucose Control and Microvascular Complications in Patients With Type 1 Diabetes.
Marchand L; Kawasaki-Ogita Y; Place J; Fayolle C; Lauton D; Boulet F; Farret A; Renard E
J Diabetes Sci Technol; 2017 Sep; 11(5):924-929. PubMed ID: 28303725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
